Both FIB-4 and NT-proBNP have been shown to be independently associated with cardiovascular mortality and all-cause mortality in patients with metabolic (dysfunction)-associated steatotic liver disease, a condition frequently associated with type 2 diabetes mellitus, suggesting that their combined use may provide a useful risk stratification tool in clinical practice [56]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.